Zofran Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Upcoming Status Conference in Federal Birth Defects Litigation
February 22, 2016 (PRLEAP.COM) Business NewsFebruary 22, 2016 - The federal multidistrict litigation involving hundreds of Zofran birth defects lawsuits (http://www.rxinjuryhelp.com/zofran/lawsuit/) continues to move forward in the U.S. District Court, District of Massachusetts. According to court documents, the next Status Conference will be convened on February 23rd at 1:30 p.m. E.S.T. (In Re Zofran Products Liability Litigation – MDL 2657).
A Proposed Agenda submitted by the parties indicates that a number of issues will be addressed at that time, including:
"Our attorneys continue to receive inquiries from families who are concerned that Zofran may have caused their child's birth defect. We are looking forward to tomorrow's conference, as well as additional progress in the multidistrict litigation in the weeks and months ahead," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm offers free legal reviews to families whose children may have been harmed due to pre-natal Zofran exposure during the first trimester of pregnancy.
Court documents indicate that at least 223 Zofran lawsuits are now pending in the District of Massachusetts, all of which were filed on behalf of children who were allegedly born with heart defects, oral clefts, and other congenital abnormalities due to their mothers' use of the medication in the first three months of pregnancy. Plaintiffs claim that GlaxoSmithKline aggressively marketed Zofran as an appropriate treatment for pregnancy-related nausea and vomiting, even though it has never been proven safe and effective for this indication. They further accuse the company of concealing evidence linking Zofran to birth defects, and of failing to provide doctors and patients with adequate warnings about this risk.
Zofran is currently indicated only for the treatment of nausea and vomiting experienced by post-op surgery patients or those undergoing certain cancer therapies. The U.S. Food & Drug Administration (FDA) has declared Zofran a Pregnancy Category C medication, which indicates that its effects on a developing pregnancy have not been well studied. In 2012, GlaxoSmithKline agreed to pay $3 billion to resolve illegal marketing charges with the U.S. Department of Justice that involved a number of its medications. Among other things, the company had been accused of promoting Zofran as an off-label treatment for expectant mothers who experience nausea and vomiting.
Children who allegedly suffered serious birth defects due to their mothers' use of Zofran during the first trimester of pregnancy may be entitled to compensation from GlaxoSmithKline. To find out more about filing a Zofran lawsuit, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP